How much cash does Veradermics generate?

Veradermics (MANE) generated -$46.3M in operating cash flow over the trailing twelve months.

What is Veradermics 's free cash flow?

After $19.0K of capital expenditures, Veradermics 's free cash flow was -$46.3M over the trailing twelve months.

Where does Veradermics 's cash flow data come from?

Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Veradermics MANE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$27.23M—	——	——	——	-$12.4M-87.3%
Stock-based compensation	$5.26M—	——	——	——	$213K+241%
Change in accounts payable	-$1.06M—	——	——	——	-$686K-525%
Change in accrued liabilities	-$1.37M—	——	——	——	-$862K-371%
Change in other assets	$174K—	——	——	——	$0-100%
Change in other liabilities	-$8K—	——	——	——	-$7K—
Other working capital changes	——	-$10.75K0.0%	-$10.75K0.0%	-$10.75K0.0%	-$10.75K+92.5%
Net cash from operating activities	-$21.17M—	——	——	——	-$13.32M-125%
Capital expenditures	$0—	——	——	——	$19K—
Purchases of investments	$122.99M—	——	——	——	$15.73M—
Proceeds from maturities/sales of investments	——	$6.25M0.0%	$6.25M0.0%	$6.25M0.0%	$6.25M—
Net cash from investing activities	-$101.3M—	——	——	——	-$15.75M—
Repayments of debt	——	$0—	$0—	$0—	$0-100%
Proceeds from issuance of common stock	$11K—	——	——	——	$0—
Proceeds from issuance of preferred stock	$0—	——	——	——	$8.42M—
Net cash from financing activities	$269.11M—	——	——	——	$8.42M-44.3%
Net increase (decrease) in cash	$146.65M—	——	——	——	-$20.64M-324%
Interest paid	——	$0—	$0—	$0—	$0-100%
Income taxes paid	——	$0—	$0—	$0—	$0—
Accretion (Amortization) of Discounts and Premiums, Investments	$73K—	——	——	——	$13K—
Accrued Interest Earned, Investments	——	$161.75K0.0%	$161.75K0.0%	$161.75K0.0%	$161.75K—
Increase (Decrease) in Accrued Interest Receivable, Net	$1.5M—	——	——	——	$0—
Increase (Decrease) in Prepaid Expense and Other Assets	-$4.36M—	——	——	——	-$79K-127%
Other Noncash Income (Expense)	-$6K—	——	——	——	-$2K+98.6%
Research and development expenses paid with convertible and promissory notes	——	$0—	$0—	$0—	$0-100%
Non-cash research and development services	$621K—	——	——	——	$357K+41.2%
Proceeds From Sale And Maturity Of Available For Sale Securities	$21.69M—	——	——	——	$0—
Payments Of Stock Issuance Costs	——	$111.75K0.0%	$111.75K0.0%	$111.75K0.0%	$111.75K+58.0%
Net proceeds from sales of subsidiary shares	$269.1M—	——	——	——	$0—
Repayments Of Notes Payable	——	$0—	$0—	$0—	$0-100%
Conversion of other receivable in exchange for research and development services to subscription receivable	——	$0—	$0—	$0—	$0-100%
Value of common stock issued to settle convertible senior notes	——	$0—	$0—	$0—	$0-100%
Unrealized loss on marketable securities	-$584K—	——	——	——	$0—
Issuance of convertible note for accounts payable	——	$0—	$0—	$0—	$0-100%
Notes Issued1	——	$0—	$0—	$0—	$0-100%
Proceeds From Notes Payable	——	$0—	$0—	$0—	$0-100%
Leased assets obtained in exchange for operating lease liabilities	$0—	——	——	——	$90K—
Modification of Series B Redeemable Convertible Preferred Stock	——	$4.2M—	——	——	——
Stock issued for services	——	$0—	$0—	$0—	$0-100%
Income Taxes Paid, Net	——	$0—	$0—	$0—	$0—
Free cash flow	-$21.17M—	——	——	——	-$13.34M-125%
Free cash flow	-$21.17M—	——	——	——	-$13.34M-125%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Veradermics generate?: Veradermics (MANE) generated -$46.3M in operating cash flow over the trailing twelve months.
What is Veradermics 's free cash flow?: After $19.0K of capital expenditures, Veradermics 's free cash flow was -$46.3M over the trailing twelve months.
Where does Veradermics 's cash flow data come from?: Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.